A phase II trial involving capmatinib and nabulizumab as secondary treatments for advanced/metastatic EGFR wild-type NSCLC patients, who had not received anti-PD-1/PD-L1 before, revealed that a group with elevated MET expression (evidenced by immunohistochemistry in 50% of tumor cells = 3 + or gene copy number (GCN) 5 or IHC in METex14 + = 2 +) exhibited a six-month PFS rate of 68.9%
their evidence comes from rodent and cell-culture research, leaving any muscle-growth claim for these three compounds preliminary and non-human in origin
The point-line network model constructed from activity trajectories provides an intuitive representation of the physical and dynamic attributes of urban vitality
Without adequate filaggrin, the outermost skin layer becomes porous
The time course of methylene blue in whole blood after IV administration showed a multiphasic time course with an estimated terminal half-life of 5.25 hr
To enhance the consistency of hospital standard charge information and the comparability of the median allowed amount, and the 10th percentile and 90th percentile allowed amounts, and in accord with what commenters had earlier suggested in the CY 2024 OPPS/ASC final rule with comment period, in the CY 2026 OPPS/ASC proposed rule (90 FR 33476), we proposed to require that hospitals only use EDI 835 ERA transaction data to calculate and encode the allowed amounts
